Macrogenics, based in Rockville, MD, is a biopharmaceutical company dedicated to developing and commercializing cutting-edge monoclonal antibody-based therapeutics for cancer treatment. With a broad pipeline of investigational product candidates and leading multispecific antibody technology platforms, the company focuses on creating breakthrough biologics to address unmet medical needs.
Driven by a commitment to innovation and patient care, Macrogenics boasts fully-integrated antibody-based development capabilities, including GMP manufacturing, to bring life-changing medicines to those in need. Their emphasis on developing innovative therapies for cancer patients underscores their mission to make a meaningful impact in the field of biopharmaceuticals.
Generated from the website